Compounded and brand-name GLP-1 medications: key differences
They are not the same product and they do not follow the same regulatory path. This comparison separates what is known about approved brand drugs from what must be evaluated for an individual compounded preparation.
Side-by-side comparison
| Topic | FDA-approved brand drug | Compounded preparation |
|---|---|---|
| FDA status | The finished product was reviewed and approved for specific indications. | It is not FDA-approved and is not brand-identical. |
| Clinical evidence | Trials apply to the studied product, dose, and formulation. | Brand-trial results cannot be transferred as an effectiveness promise. |
| How it reaches a patient | A licensed pharmacy dispenses the prescribed product. | If applicable requirements are met, a licensed pharmacy prepares and dispenses a prescription for an identified patient. |
| Availability | Depends on indication, prescription, coverage, and inventory. | Depends on medical need, prescription, legal requirements, location, and pharmacy capacity. |
| Cost | Varies by product, dose, coverage, and manufacturer program. | Varies by prescription and pharmacy. The $119 medical review is separate from medication cost. |
What the 503A pathway means
Section 503A sets conditions for certain preparations made by a licensed pharmacy for an identified patient based on a valid prescription. Meeting those conditions does not make a compounded preparation FDA-approved.
For a copy of a commercially available drug, federal law limits compounding regularly or in inordinate amounts. A significant difference must be based on the individual patient's need and determined by the prescriber. Cost or a general formulation preference alone should not be presented as an automatic justification.
How to evaluate an option without assuming equivalence
- 1. Confirm the indication.
Ask which diagnosis and individual medical need guide the recommendation. - 2. Confirm the pharmacy.
Verify its active state license and public disciplinary history. - 3. Confirm the cost.
Get the evaluation fee, separate medication price, and follow-up charges in writing.
Primary sources
Confirm availability first
If care is available for your location, the medical review is $119. Medication is priced separately, and a prescription is never guaranteed.
Check availabilityExpanded decision guide
How the two categories differ at a glance
An FDA-approved finished drug and a compounded preparation enter care through different pathways. Approval means FDA reviewed a particular finished product for its labeled use, manufacturing controls, and supporting evidence. A compounded preparation is made for an identified patient under applicable compounding conditions. It is not FDA-approved, not brand-identical, and should not inherit an approved product's trial results.
| Decision point | FDA-approved finished product | Compounded preparation |
|---|---|---|
| Evidence | Product-specific labeling and reviewed studies | No FDA premarket review of the finished preparation |
| Reason for use | Fits the labeled indication and clinical plan | Requires a patient-specific clinical rationale and compliance with the applicable compounding conditions |
| Dispensing | Filled by a pharmacy under the prescription | Fulfillment depends on a dispensing pharmacy verified for the patient and location; the clinic does not manufacture or dispense |
| Expectation | Results and risks still vary by person | Results and risks vary, and brand results cannot be assumed |
When an approved product may fit
An approved product is often the clearer evidence path when it is clinically appropriate, accessible, and acceptable to the patient. The decision still requires review of indication, contraindications, other medicines, pregnancy plans, prior response, side effects, total cost, and follow-up. Approval does not make a drug right for every person.
When a compounded preparation may be discussed
FDA recommends an approved drug when it can meet the patient's medical need. A compounded preparation may enter a patient-specific discussion when an approved option cannot meet that need and the prescription can be filled lawfully. That clinical judgment is not itself the 503A significant-difference legal test. If that exception to FDA's commercially available product duplication policy is relied on, the prescriber must determine and document that a change in the compounded drug produces a significant difference for the identified patient.
The clinical rationale, legal basis, exact preparation, pharmacy, directions, and follow-up should be clear before payment or use. Cost or preference alone should not be presented as automatically satisfying a federal compounding condition.
Neutral warning signs
- A prescription or outcome is promised before medical review.
- The dispensing pharmacy's legal name will not be provided.
- A preparation is described as identical to an approved product.
- Trial results are quoted without naming the exact studied product, population, and duration.
- Evaluation, medication, renewal, follow-up, and cancellation costs are blended or unclear.
Primary and official source trail
Read each source for the exact product, population, date, method, and limitation. A source supports only the claim it actually studied or the policy it actually states.
Frequently asked questions
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Wegovy and Ozempic are FDA-approved finished products. Compounded semaglutide is not FDA-approved, is not brand-identical, and results vary by individual.
Does brand-drug trial evidence predict the result of a compounded preparation?
No. A trial supports the product, dose, and formulation that were studied. Its results should not be presented as evidence of effectiveness for a different compounded preparation.
Who prepares and dispenses a 503A preparation?
If prescribed, the licensed pharmacy prepares and dispenses the prescription for the identified patient. The clinic performs the medical evaluation but does not manufacture or dispense the medication.
When may a compounded preparation be considered?
FDA states that a compounded drug may be appropriate when a patient's medical need cannot be met by an available approved drug. The prescriber and dispensing pharmacy are responsible for the applicable decision and documentation.
What does the $119 medical review cover?
The $119 fee covers the medical evaluation and, if approved, the prescribing decision. Medication is priced separately. Availability depends on location, clinical evaluation, and a pharmacy able to dispense legally.
This content is educational and does not replace a medical evaluation. No outcome is guaranteed. Do not start, stop, or change a medication without speaking with your health care professional.